PML related to number of Tysabri infusions, FDA says
This article was originally published in Scrip
The US FDA has received reports of two further cases of the rare and potentially fatal brain infection, progressive multifocal encephalopathy (PML), in multiple sclerosis patients receiving Biogen Idec's Tysabri (natalizumab), bumping the number of confirmed cases up to 13. However, it is not requiring changes to the drug's label.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.